###### Strengths and limitations of this study

-   Embedded in the existing cervical screening programme.

-   Cross-regional study including large number of women.

-   Six-year screening interval in human papillomavirus arm estimated based on observed data.

Introduction {#s1}
============

There are two preventive measures against cervical cancer: the long-time practised cervical cancer screening aiming to find precancerous lesions before they develop into invasive cancer and the newer vaccination against human papillomavirus (HPV), a necessary cause of cervical cancer.[@R1] In Denmark, as well as in many other countries, both measures are used. However, there is no international consensus on the best way to combine the two. Trial23 aims to contribute in answering this question.

In 2016, the first birth cohort of Danish women offered HPV vaccination as girls entered the cervical screening programme. So far, the national recommendations for cervical screening have not changed. Denmark was among the first countries to introduce HPV vaccination and is consequently one of the first countries to face the challenge of how to screen HPV vaccinated women. Trial23 aims to optimise screening for women offered HPV vaccination as girls.

In 2008, Danish girls born in 1993--1995 were offered free HPV vaccination with the quadrivalent Gardasil (Merck). They were 13--15 years old at the time. Since 2009, HPV vaccination has been part of the Danish child vaccination programme for 12-year-old girls.[@R2] The vaccine high risk (HR) HPV types 16 and 18 are present in 70% of cervical cancers.[@R3] Vaccine studies have shown a protection of almost 100% against vaccine type (HPV 16 and 18) related cervical intraepithelial neoplasia (CIN) 2+ in women HPV naive at the time of vaccination[@R4] and a protection of 43% against all CIN2+.[@R6] As HPV is a sexually transmitted infection, vaccination should preferably take place before sexual debut.

Cervical screening in Denmark targets women aged 23--64 years. From ages 23-- to 49 years, women are offered cytology-based screening every third year, and for 50 years and above, every fifth year. Liquid-based cytology is used nationwide. Women above age 60 years are offered an HPV-DNA 'exit-test'.[@R7] Most of the samples are taken in general practice. Coverage is about 75% for all age groups[@R8] and around 60% for women aged 23--24 years.[@R9]

Several countries are implementing primary HPV testing, such as Australia, New Zealand, Sweden and the Netherlands.[@R10] Primary HPV testing has been compared with cytology in large randomised controlled trials (RCTs) showing that HPV testing provides a better protection against cervical cancer.[@R14] Indeed, the 6-year protection against CIN3+ after a negative HPV test was higher than the 3-year protection after a negative cytology test.[@R15] For young women, data from A Randomised Trial In Screening To Improve Cytology (ARTISTIC) trial show similar results.[@R16] However, the European Guidelines recommend against primary HPV screening in women younger than 30 years because of a risk of increased overdiagnosis and referral for colposcopy.[@R17] This is due to a high HPV prevalence combined with a high regression rate of lesions in young women.[@R18] A Danish study estimated that 46% of unvaccinated Danish women aged 20--23 years have an HR HPV infection.[@R19] This underlines the need for triage in primary HPV testing of young women.

Objective {#s1a}
---------

Women HPV vaccinated as girls are better protected against cervical cancer than previous birth cohorts. HPV vaccination is expected to prevent 70% of cervical cancers. So even in these women, some screening may still be beneficial. It is therefore pertinent to find less intensive screening schemes for women HPV vaccinated as girls.

The objective of this study is to investigate if primary HPV testing with cytology triage every 6 years protects women offered HPV vaccination as girls against CIN3+ to the same extent as the current cytology-based screening every 3 years. The longer screening interval would reduce the burden of screening in HPV-negative women by reducing the number of screening rounds. In this way the screening programme could take into account that the optimal balance between screening-related harms and gains differs between HPV-vaccinated women and previous birth cohorts.

Hypothesis {#s1b}
----------

No difference between cumulative risk of CIN3+ after two rounds of primary HPV screening with cytology triage and three rounds of cytology-based screening (present screening programme).

Methods and analysis {#s2}
====================

Trial23 is a method study embedded in the Danish cervical screening programme.

Originally, the intention was to compare the present screening method (cytology) to primary HPV testing with cytology triage with different time intervals. However, the Danish Ethical Committee required informed consent for permission to randomise screening scheme. Collection of informed consent was not feasible due to the large number of participants and decentralised sampling procedure. For this reason, the trial is undertaken as a method study as defined by the Danish Ethical Committees. However, although the design has changed, the objective of the trial is unchanged, and the comparison between the two envisioned schemes will be calculated from the collected data. We therefore operate with the terms 'HPV' and 'present program arm'.

In the method study, the HPV test is made as a cotest on the cytology sample material without affecting the screening programme. The HPV test does not affect the clinical management of the woman.

Study design {#s2a}
------------

Women are randomly allocated 1:1 for HPV or present programme arm:HPV arm: cytology and HPV-test every third year.Present programme arm: cytology every third year

There are four possible scenarios for women in the HPV-arm (see [figure 1](#F1){ref-type="fig"}):HPV-negative, cytology normal.HPV-negative, cytology abnormal.HPV-positive, cytology normal.HPV-positive, cytology abnormal.

![Trial flow for participation in cervical screening. \*Abnormal cytology, high grade: HSIL, ASCH and AIS (Bethesda classification). \*\*Abnormal cytology, low grade: ASCUS, AGC and LSIL (Bethesda classification). \*\*\*Colposcopy with biopsy. AGC, atypical glandular cells; AIS, adenocarcinoma in situ; ASCH, atypical squamous cells cannot exclude; ASCUS, atypical squamous cells of undetermined significance; HPV, human papillomavirus; HSIL, high grade squamous intraepithelial lesions; LSIL, low grade squamous intraepitehlial lesions.](bmjopen-2017-020294f01){#F1}

Among these scenarios only the HPV-negative/cytology abnormal differs from primary HPV screening with cytology triage. In this case, cytology triage would not have been performed and abnormal cytology would not have been found.

In the present screening programme, all regions refer women with high-grade cytology changes to colposcopy and biopsy. In case of low-grade cytology changes, some regions use HPV triage, while others recommend cytology control after 6 months. These regional practices are incorporated into the HPV arm (see [figure 1](#F1){ref-type="fig"}).

In order to avoid increased referral for colposcopy and overdiagnosis when young women are screened with HPV tests, the cytology determines the course of action. A woman with a positive HPV test and normal cells at baseline is retested for both HPV and cytology in the next round 3 years later, as in the new Swedish cervical screening programme.[@R11]

Setting {#s2b}
-------

The study is set in four out of five Danish regions: Central Denmark Region, North Denmark Region, Region Zealand and part of Region of Southern Denmark (see [figure 2](#F2){ref-type="fig"}). Cervical screening is centralised to one or a few pathology departments in each region.

![Map over the geographical areas covered by Trial23.](bmjopen-2017-020294f02){#F2}

Timeline {#s2c}
--------

Trial23 commenced on 1 February 2017 and will run over three screening rounds, that is, 7--8 years (see [table 1](#T1){ref-type="table"}). The final results will be analysed when follow-up is completed. Results of the baseline screening round will be analysed after 1 October 2018 allowing for at least 3 months from invitation to screening and 6 months for follow-up in case of abnormal screening result.

###### 

SPIRIT flow chart for Trial23

  Study period                                                                                                                                   
  ------------------------------ ---------------- ------------------------------- ------------------------------ ------------------------------- -----------------
  Timepoint                      January 2017\*   February 2017--September 2018   January 2020--September 2021   January 2023-- September 2024   1 October 2025†
  Enrolment                                                                                                                                      
   Eligibility                   X                                                                                                               
   Allocation                    X                                                                                                               
  Intervention                                                                                                                                   
   HPV arm (CYT+HPV)                              \<---\>                         \<---\>‡                       \<---\>                         
   Present programme arm (CYT)                    \<---\>                         \<---\>                        \<---\>                         
  Assessment                                                                                                                                     
   Baseline screen                                X                                                                                              
   Second screen                                                                  X                                                              
   Third screen                                                                                                  X                               
   Final                                                                                                                                         X

\*All women born in 1994 living in Denmark in January 2017 were randomly allocated to HPV or present programme arm.

†End-of-study allowing for 1 year extra for women followed up due to abnormal cytology in former screening rounds.

‡Women with positive HPV test and normal cytology at baseline are retested after 3 years for both HPV and cytology.

CYT, cytology; HPV, human papillomavirus; SPIRIT, Standard Protocol Items: Recommendations for Interventional Trials.

Target population {#s2d}
-----------------

Women born in 1994 turning 23 years in 2017 and living in the geographical areas covered by the trial form the target population (see [table 2](#T2){ref-type="table"}). These women were 14 years old when they were offered HPV vaccination, and more than 80% of them had at least one dose.[@R20] According to a Danish school survey, 76% had not had their sexual debut and are therefore expected to have been HPV naïve at the time of vaccination.[@R21]

###### 

Number of eligible women residing in the geographical areas covered by Trial23

  Participating region                         Number of 23-year-old women
  -------------------------------------------- -----------------------------
  Central Denmark                              9242
  North Denmark                                3895
  Zealand                                      3705
  Southern Denmark (Soenderborg and Esbjerg)   2082
  Total                                        18 924

Eligibility criteria {#s2e}
--------------------

### Inclusion criteria {#s2e1}

Women born in 1994 and living in the geographical areas covered by the trial are automatically included.

### Exclusion criteria {#s2e2}

None.[@R22]

Randomisation {#s2f}
-------------

All persons ever living in Denmark have a personal identification number (PIN) and are included in the Danish Central Person Register (CPR). The PIN is registered at all contacts to the healthcare system. PINs for women born in 1994 and living in Denmark in January 2017 were obtained from the CPR.

These women were individually randomised to HPV or present programme arm, and this allocation was loaded onto the pathology IT systems of the participating pathology departments.

Randomisation is based on birth year instead of participation in screening, because we want to include all women to allow for intention-to-treat analysis. Women are not randomised by region in spite of the small regional differences in management and follow-up ([figure 1](#F1){ref-type="fig"}). Young women tend to be mobile, and we therefore prefer to stratify the results by region afterwards.

When a cytology sample from a randomised woman is received at a laboratory and scanned into the IT system, a 'pop-up' message appears on the screen. The 'pop-up' message shows that the woman is included in Trial23 and informs if an HPV test should be performed. A specific project code is assigned at registration.

Blinding {#s2g}
--------

The trial is unblinded.

Outcome measures {#s2h}
----------------

### Primary outcome {#s2h1}

How many cases of CIN3+ seen over two rounds of HPV screening with cytology triage with a 6 years interval, including follow-up after 3 years of women HPV-positive and cytology normal at baseline, would have been seen over three rounds of cytology screening with a 3-year interval.

CIN3+ is chosen as primary outcome because the Danish Society of Gynecology and Obstetrics[@R23] at this stage always recommends Large Loop Excision of the Transformation Zone (LLETZ).

### Secondary outcomes {#s2h2}

Number of colposcopies and number of LLETZs observed over three rounds of cytology screening and estimated over two rounds of HPV screening with cytology triage.

### Other outcomes {#s2h3}

Baseline screening results.

Intervention {#s2i}
------------

There is no real intervention in this study as it is a method study, and the result of the HPV test does not affect the clinical management of the woman. However, in the intervention arm, an HPV test is performed in addition to routine cytology screening. Cobas 4800 HPV-DNA test (Roche) is used in the trial, because it was already in routine use in the participating pathology departments. There was therefore no need for special training or extra equipment. Roche sponsors test kits for the trial. Cobas is a PCR test and detects 14 HR HPV types. It operates with three signals: HPV-16, HPV-18 and 'HPV-other' covering the remaining 12 HR HPV-types (31,33,35,39,45,51,52,56,58,59,66,68).[@R24] Standard laboratory requirements from the manufacturer are followed. As part of the trial, cervical biopsies are analysed with CINtec p16 Histology (Roche)[@R25] in addition to the routine pathology reading. Roche sponsors the p16 test kits.

Data analysis plan {#s2j}
------------------

The trial is undertaken as a non-inferiority study. If non-inferiority is proved, analysis for superiority will be carried out. Incidence rate ratios for outcomes will be calculated using Poisson regression analysis and SAS statistical software. We plan two types of analysis. First, an intention-to-treat analysis (ITT) including all randomised women followed from study start on 1 February 2017 until censoring due to death, emigration, event or end-of-study. Second, a per-protocol analysis including only screened women. Follow-up of this group will start on the date of their first cytology sample and end at censoring due to death, emigration, event or end-of-study as in the ITT population. The analyses will be stratified by HPV vaccination status and region of residence. The expected outcome of primary HPV screening with cytology triage will be estimated by including CIN3+ lesions found over the 7 years of follow-up. For the envisioned primary HPV screening with cytology triage, we will include CIN3+ lesions in women HPV-positive/cytology abnormal at baseline; HPV-positive/cytology normal at baseline, but HPV-positive/cytology abnormal at re-testing after 3 years; or HPV-positive/cytology abnormal at re-screening after 6 years. For the routine cytology screening, we will include CIN3+ lesions in women cytology abnormal, at either the baseline screen, at second screen after 3 years or at third screen after 6 years.

Power calculation {#s2k}
-----------------

The power calculation was based on the number of 23-year-old women residing in the geographic areas covered by the trial. We expect 60% of 23-year-old girls to participate in the screening programme.[@R9] Based on experience from women born in 1983, we expect 1% of the screened women to be diagnosed with CIN3+ at the first screening,[@R26] and we expect 80% of the women to be HPV vaccinated.[@R20] Furthermore, we expect the HPV vaccine efficacy for all CIN3+ to be 43%.[@R6] If there truly is no difference between the intervention and the present programme in our trial population, the upper limit of a one-sided 95% CI will exclude a difference of more than 0.35% with a power of 80% and a difference of 0.4% with a power of 90%. We expect approximately 12 000 women born in 1994 to be included in the trial, with 6000 women in each arm.

Data sources {#s2l}
------------

Data on the screening tests (cervical cytologies and HPV tests) and other screening-related outcomes for women assigned a project code will be retrieved from the Danish Pathology register and other national health registers. Use of PINs ensures that there is almost no loss to follow-up and makes it possible to merge data from different registers for the study population.

Patient and public involvement {#s2m}
------------------------------

The research question was developed in response to discussions in Denmark about future screening of HPV-vaccinated women. No representative of patient organisations participated in the design of the study. The results will be disseminated to women and healthcare authorities.

Ethics and dissemination {#s3}
========================

Ethics {#s3a}
------

The study is a method study and therefore not notifiable to the ethical committees, and informed consent is not required. In this study, all women are screened according to routine practice with cytology every 3 years as in the present screening programme and all receive usual care. The two screening schedules are compared without affecting the screening programme, and there will be no change for the individual woman. In order to avoid confusion, general practitioners and women are, therefore, not informed about the HPV test. Handling and storage of data were approved by the Danish Data Inspective Agency (SUND-2016--22).

Dissemination {#s3b}
-------------

The study protocol is registered at ClinicalTrials.gov (NCT03049553) and is made public in this protocol paper. Final and baseline results will be published in peer-reviewed, international open-access journals, listing authors according to authorship guidelines. Publication will be independent of results. Trial data will be deposited in the Danish Data Archive after end of study. Access to the data will follow the rules of the archive.[@R27]

Discussion {#s4}
==========

In Denmark, the first birth cohorts of women offered HPV vaccination as girls are currently entering the cervical screening programme. The purpose of Trial23 is to test a new, less intensive screening scheme for these women than the one currently offered in Denmark. The intention is to guide decision makers on future screening of HPV-vaccinated birth cohorts.

In Trial23, the focus is on the HPV-negative women who can benefit from a longer screening interval. Cytology is chosen as triage method, because it is in routine use in the pathology departments and of good diagnostic quality in Denmark.

Trial23 is undertaken as a method study. Originally, we planned for a public health trial with randomisation to either the new or the current screening scheme. Such public health trials have been undertaken in the other Nordic countries. In a Swedish trial, women aged 56--60 years were randomly invited to the present cytology-based screening or a new HPV-based screening scheme. The study was approved by the ethical committee who regarded participation in screening as consent.[@R28] Likewise, in Finland women aged 25--65 years were randomly invited for the present cytology-based screening or a new HPV-based screening. The local ethical committees and national authorities deemed that informed consent was not necessary because the trial was part of the routine screening programme.[@R29] In Denmark, it was not possible to get permission for such a trial.

Strengths and limitations {#s4a}
-------------------------

The major limitation of the method study design is that a 6-year screening interval in the HPV arm has to be estimated and that we have to account for the HPV-negative/cytology positive samples that would not have been found by primary HPV screening with cytology triage.

However, this design gives us the opportunity to evaluate a new screening scheme without changing the screening programme. Moreover, informed consent is not required, which is expected to ensure routine screening coverage and limited selection. It is also a strength that the study is undertaken within the existing screening programme, because the results reflect implementation directly.

As there is no real intervention, randomisation would not have been needed. However, the decision from the Ethical Committee not to allow randomisation of the screening test without informed consent came at a late stage, where the organisation and resource allocation were already in place. At that time, we could not double the number of needed HPV tests neither could we exclude participating laboratories. Therefore, we kept randomisation of the supplementary HPV test. The randomisation will furthermore allow for check of a possible difference in the cytology reading between the HPV and the cytology arms. All women are from the same birth cohort and examined in the same calendar period. However, we are not able to adjust for HPV status at the time of vaccination and risk factors such as number of sexual partners and smoking habits. Misclassification of codes in the national registers are of course present, but there is no reason to believe that it will introduce bias. In primary HPV screening with cytology triage, the HPV status is known before the cytology is read. However, our study is embedded in the routine procedure in five pathology laboratories with primary cytology screening involving many laboratory technicians and pathologists. In some laboratories, the HPV status is known before the cytology reading, while in other laboratories, cytology is read prior to the HPV testing.

Perspectives {#s4b}
------------

There is no international consensus on how to screen HPV-vaccinated women, and Denmark is one of the first countries to face this challenge. However, Australia implemented HPV vaccination already in 2007 and will in 2017 implement primary HPV screening with partial genotyping and cytology triage every 5 years for HPV-vaccinated and unvaccinated women aged 25--69 years. COMPASS (a Randomised Controlled Trial of Primary HPV Testing for Cervical Screening in Australia) running in parallel aims to compare the new screening programme to cytology every two and a half years.[@R10] In addition, a consensus on cervical screening in HPV-vaccinated women has been reached in Italy,[@R30] where HPV vaccination started in 2008. Italy will change to primary HPV screening in 2021, when the first birth cohorts of women HPV vaccinated at age 12 years enter the screening programme. Age at start of screening will change from the current 25 to 30 years, and the new screening protocol will be used only for vaccinated women until herd immunity is sufficient for all women to receive the same screening regardless of vaccination status.

In Denmark, the next seven birth cohorts of women entering the cervical screening programme were offered HPV vaccination at age 12--13 years with high coverage around 90% for first dose.[@R20] However, recently HPV vaccination coverage has dropped in Denmark due to public concern about possible side effects.[@R31] Coverage is now 46% for first dose for girls born in 2004.[@R20] Japan has abandoned HPV vaccination because of attention to possible side effects,[@R32] and decreasing coverage is at present also observed in the Netherlands[@R33] and Ireland.[@R34] If HPV-vaccination coverage regains its former high level in Denmark, the same screening scheme would be applicable for all women because of high herd immunity. However, if coverage stays low, a similar approach as the Italian with different screening schemes for vaccinated and unvaccinated women may be considered.

Trial status {#s5}
============

Ongoing.
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